About StemCells
StemCells was a Healthcare company based in Newark (United States) founded in 1992. It provides stem cell-based therapeutics for central nervous system disorders. It operates on a B2B model. The company is recorded as dissolved. Its focus areas include Biotechnology, Stem Cell Therapeutics and CNS Disorders. Its legal entity is STEMCELLS INC. Its competitors include Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, PureTech Health and Biohaven Pharmaceutical and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
StemCells, based in Newark, focuses on providing healthcare solutions, advancing biotech innovations, stem cell therapeutics, and cns disorders. Provides stem cell-based therapeutics for central nervous system disorders. The company prioritizes operational excellence, innovation, and customer-centric approaches for success. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Newark, United States
- SectorsHealthcare
- Website stemcellsinc.com
- Social X
- Legal Name Stemcells Inc
- Latest Funding Round$98.69K (USD), Grant
Mar 2010
- Investors
Funding Insights of StemCells
- Total Rounds 2
- Last Round Grant — $98,685
- First Round $98,685
(Feb 2010)
- Investors Count 1
All 2 funding rounds of StemCells with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in StemCells
StemCells has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for StemCells
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of StemCells
5 people are tracked at StemCells (3 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Ian Ey | CEO | Leadership |
Stephen Huhn M.D. | Vp, Clinical Research And Chief Medical Officer | Leadership |
Stan Tamaki | Director Of Antibody Research And Development | Leadership |
Joseph Gilbert | Senior Clinical Research Associate | Team |
Erlina Pali | Technical Scientist | Team |
Complete people profiles for StemCells
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of StemCells
3 dated milestones of StemCells across 18 years, from founding to its latest funding, stage changes and deals.
- Founded StemCells is founded.
- Funding First funding round of $99K.
- Funding Latest funding round, Grant, of $99K.
Competitors of StemCells
StemCells has 9 listed competitors in our database, 8 of them funded. They include Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, PureTech Health and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| lundbeck.com | 1915 | Copenhagen, Denmark | – | 393 | Drugs for CNS disorders are developed and advanced. | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. | |
| biohavenpharma.com | 2014 | New Haven, United States | $84.1M | 932 | Therapies for neurological and neuropsychiatric diseases are developed. | |
| askbio.com | 2001 | Durham, United States | $235M | – | Gene and protein therapies are developed for treating various diseases. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| karunatx.com | 2009 | Boston, United States | $132.1M | 339 | Therapies for psychosis and cognitive impairment are developed. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders |
Detailed competitors of StemCells
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of StemCells
Websites that share an audience with StemCells (stemcellsinc.com).
Websites whose visitors overlap most with StemCells. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pluristem.com | 100% | – | – | View details | |
| intercytex.com | 100% | – | – | View details | |
| advancedcell.com | 91% | 1.5K | #9,773,682 | View details | |
| stemcell.com | 78% | 262.4K | #179,047 | View details | |
| geron.com | 41% | 11K | #2,181,363 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for StemCells
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
10 companies that operate in the same segment as StemCells (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about StemCells
StemCells was founded in 1992 and raised its 1st funding round 18 years after it was founded.
StemCells is headquartered in Newark, United States. It is registered at Newark, New Jersey, United States.
StemCells, based in Newark, focuses on providing healthcare solutions, advancing biotech innovations, stem cell therapeutics, and cns disorders. Provides stem cell-based therapeutics for central nervous system disorders. The company prioritizes operational excellence, innovation, and customer-centric approaches for success. It continues to evolve, meeting industry challenges with strategic approaches.
StemCells's top competitors include Jazz Pharmaceuticals, Neurocrine and Biohaven Pharmaceutical.
StemCells has 1 investor. Key investors include HHS.
StemCells operates through Stemcells Inc.